<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957511</url>
  </required_header>
  <id_info>
    <org_study_id>V235</org_study_id>
    <nct_id>NCT04957511</nct_id>
  </id_info>
  <brief_title>Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy</brief_title>
  <official_title>Pilot Feasibility Study of the Interplay Between the Host Gut Microbiome and Efficacy of Treatment for Advanced or Recurrent Gynecological Cancer Patients Receiving Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Viome</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      30 participants with advanced or recurrent gynecological cancer from are enrolled for this&#xD;
      study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal&#xD;
      swab and receive food dietary recommendation. Additional samples are collected for results&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 patients diagnosed with advanced or recurrent gynecological cancer who plan to receive&#xD;
      immunotherapy treatment with a checkpoint inhibitor at AHMG AdventHealth Orlando&#xD;
      Gynecological Oncology Group are recruited. Patients will be recruited 1-2 weeks prior to the&#xD;
      beginning of treatment and appropriate informed consent will be obtained. Fecal samples;&#xD;
      blood; saliva and vaginal swab samples will be collected among participants prior to their&#xD;
      first treatment, after four doses of immunotherapy, and again at the completion of&#xD;
      immunotherapy (follow-up). These 4 biomarker samples will undergo metatranscriptomic&#xD;
      analysis, also known as RNAseq, method of sample analysis. Only RNA molecules are sequenced,&#xD;
      while DNA is degraded. for bacterial community analysis. These findings will help to design a&#xD;
      future study to examine the role of the gut microbiome in antitumor immunity and its effect&#xD;
      on immune checkpoint inhibitor therapy for advanced or recurrent gynecological cancer. NHANES&#xD;
      Food Frequency Questionnaire will be collected prior to participants' first treatments.&#xD;
&#xD;
      The short-term goals of this pilot study are to obtain preliminary data on the gut bacterial&#xD;
      microbiome of patients with advanced or recurrent gynecological cancer. The long-term goals&#xD;
      of this study is to begin to understand how the gut microbiome changes within an individual&#xD;
      patient undergoing immunotherapy, to gut microbiome differs among patients undergoing&#xD;
      immunotherapy, and to examine whether the gut microbiome is associated with the response to&#xD;
      cancer immunotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome change through analysis of biological samples (fecal specimen, blood, vaginal swab, oral mucosal swab).</measure>
    <time_frame>~2 years</time_frame>
    <description>Changes are measured between the genetic microbiome signatures of advanced or recurrent gynecological cancer patients who are receiving immune checkpoint inhibitors.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gynecologic Cancer</condition>
  <condition>Immunotherapy</condition>
  <condition>Gut Microbiome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Only RNA molecules are sequenced, while DNA is degraded. The AdventHealth Research Laboratory&#xD;
      will process the de-identified blood samples and store; Plasma, Serum and Buffy Coat for&#xD;
      future analysis. The Advent Health Research Laboratory will store these samples in the&#xD;
      biorepository, inventory and chain of custody will be managed by the STARLIMS program.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced or recurrent gynecological cancer patients receiving immunotherapy from AHMG&#xD;
        Advent Health Orlando Gynecologic Oncology Group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult females &gt; 18 years old&#xD;
&#xD;
          -  Advanced or recurrent gynecological cancer patients from AHMG Advent Health Orlando&#xD;
             Gynecologic Oncology Group&#xD;
&#xD;
          -  Patients for whom an immunotherapy regimen has been ordered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to provide fecal specimens at three time points&#xD;
&#xD;
          -  Patients unable to read or understand informed consent&#xD;
&#xD;
          -  Taking medications that may affect gut microbiome:&#xD;
&#xD;
               -  Proton pump inhibitors (PPIs)&#xD;
&#xD;
               -  Metformin&#xD;
&#xD;
               -  Antibiotics&#xD;
&#xD;
               -  Laxatives&#xD;
&#xD;
          -  Patients who are receiving investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult females &gt;18 years old</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Momo Vuyisich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Viome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Momo Vuyisich, PhD</last_name>
    <phone>855 958 4663</phone>
    <email>momo@viome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronda Ramsey, MSHS</last_name>
    <phone>425 300 6933</phone>
    <email>ronda.ramsey@viome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Chestnut</last_name>
      <phone>407-303-2451</phone>
      <email>Jessica.Chestnut@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Nathalie McKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Holloway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Kendrick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biome</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Gastrointestinal</keyword>
  <keyword>Immune check point inhibitors</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Diet</keyword>
  <keyword>Viome</keyword>
  <keyword>ICI</keyword>
  <keyword>ICIs</keyword>
  <keyword>RNAseq</keyword>
  <keyword>Anti-tumor immunity</keyword>
  <keyword>Cancer</keyword>
  <keyword>Gynecology</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

